Regeneron (REGN) Stock Looks Discounted As It Holds A 24% Gain

Regeneron Pharmaceuticals has delivered a 24.1% return over the past year, yet the stock still screens as undervalued on broad valuation checks. This raises the question of whether the market is fully pricing in its recent progress and setbacks.

• A 24.1% one year return suggests sentiment toward Regeneron Pharmaceuticals has been constructive, even with shorter term pullbacks earlier in the year.
• Regulatory momentum around dupilumab and other key products can support higher earnings expectations. However, recent disappointing pipeline trial results and a planned US$127m research and development charge may limit how much investors are willing to pay for that growth.
• Regeneron Pharmaceuticals currently passes 6 of 6 valuation checks, indicating that on Simply Wall St's broader framework the stock leans cheap relative to its fundamentals and peers, which you can see in more detail at 6/6 valuation checks.

The issue now is whether Regeneron Pharmaceuticals' recent share price strength has already captured this apparent discount, or if there is still room for valuation to catch up further.

Find out why Regeneron Pharmaceuticals' 24.1% return over the last year is lagging behind its peers.

Does Regeneron Pharmaceuticals Look Undervalued on Earnings?

The P/E ratio is a useful cross check for Regeneron Pharmaceuticals because the company generates positive earnings and is covered by a broad analyst base. Regeneron trades on a P/E of about 15.6x, which sits below the biotech industry average of roughly 17.1x and well under the peer group average of around 23.7x.

On Simply Wall St's framework, a more tailored fair P/E for Regeneron Pharmaceuticals is about 25.0x, based on factors such as growth outlook, margins, size and risk profile. That is meaningfully higher than the current 15.6x, and this suggests the market is applying a sizeable discount relative to what this model implies. Despite recent headlines around a US$127m R&D charge and mixed pipeline trial results, the stock still prices in materially less than this fair multiple.

On the P/E multiple, Regeneron Pharmaceuticals appears undervalued relative to both this fair value marker and its typical biotech peers.

See what the numbers say about this price — find out in our valuation breakdown.

The Regeneron Pharmaceuticals Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Regeneron Pharmaceuticals pick up where the valuation checks leave off by setting out what paths for revenue, margins and earnings would need to play out for the stock to be worth significantly more or less than it is today on the market. Where a single ratio or model gives you one figure, these narratives unpack the future that figure rests on so you can watch how Regeneron Pharmaceuticals' actual progress lines up over time.

Community views on Regeneron Pharmaceuticals sit quite far apart, with one camp focused on cash flow support and the other on pipeline and pricing risk.

Bull case: 19% undervalued

"Bullish analysts highlight Regeneron Pharmaceuticals' core commercial assets, including Dupixent and Eylea HD, as important supports for earnings, even as expectations for the LAG-3 and fianlimab programs are reduced in their models…"

Read the full Bull Case to see why Regeneron Pharmaceuticals could be undervalued

Bear case: 6% overvalued

"Bearish analysts focus on the failed Phase 3 fianlimab and LAG-3 melanoma trials as key reasons for multiple price target cuts, citing reduced revenue contribution from these programs and a hit to confidence in Regeneron's pipeline execution…"

Read the full Bear Case to see why Regeneron Pharmaceuticals could be overvalued

Do you think there's more to the story for Regeneron Pharmaceuticals? Head over to our Community to see what others are saying!

The Bottom Line

Regeneron Pharmaceuticals screens as undervalued on market multiples, with the current P/E sitting below both industry and peer averages and below the tailored fair ratio discussed earlier. The broader valuation checks also lean supportive, which means the discount does not rest on a single metric. From here, what matters most is whether Regeneron Pharmaceuticals can keep converting its core products into resilient earnings while managing pipeline and R&D setbacks. That will decide whether the current discount reflects opportunity or an ongoing caution premium on execution risk.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com